A bone marrow transplant process co-developed by investigators at the Johns Hopkins Kimmel Cancer Center is safe and curative for adults with sickle cell disease, according to results of a trial completed at Johns Hopkins and about 20 additional cancer centers nationwide and in London. The treatment, available at multiple U.S. medical centers, is a viable and less costly alternative to recently approved gene therapy products for sickle cell disease, the authors say.

During this type of transplant, called reduced-intensity haploidentical bone marrow transplantation, bone marrow is given by a “half-matched” donor, such as a parent, sibling, child, niece, nephew, aunt, uncle or cousin of the patient. This means the proteins that help the body’s immune system function, and which are present on a donor’s marrow cells, must match at least half of those proteins on the recipient’s cells to be a good fit and to not attack the recipient’s body after the transplant.